Our top pick for
Kronos Bio Inc is a biotechnology business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio employs 90 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$16.51|
|52-week range||$16.10 - $39.61|
|50-day moving average||$21.27|
|200-day moving average||$23.04|
|Wall St. target price||$42.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.55%|
|1 month (2021-09-22)||-27.84%|
|3 months (2021-07-22)||-24.72%|
|6 months (2021-04-22)||-28.03%|
|1 year (2020-10-21)||-48.85%|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-20.52%|
|Return on equity TTM||-50.3%|
|Market capitalisation||$943.9 million|
TTM: trailing 12 months
There are currently 4.3 million Kronos Bio shares held short by investors – that's known as Kronos Bio's "short interest". This figure is 5.3% up from 4.1 million last month.
There are a few different ways that this level of interest in shorting Kronos Bio shares can be evaluated.
Kronos Bio's "short interest ratio" (SIR) is the quantity of Kronos Bio shares currently shorted divided by the average quantity of Kronos Bio shares traded daily (recently around 245515.21367521). Kronos Bio's SIR currently stands at 17.55. In other words for every 100,000 Kronos Bio shares traded daily on the market, roughly 17550 shares are currently held short.
To gain some more context, you can compare Kronos Bio's short interest ratio against those of similar companies.
However Kronos Bio's short interest can also be evaluated against the total number of Kronos Bio shares, or, against the total number of tradable Kronos Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kronos Bio's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Kronos Bio shares in existence, roughly 80 shares are currently held short) or 0.0981% of the tradable shares (for every 100,000 tradable Kronos Bio shares, roughly 98 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kronos Bio.
Find out more about how you can short Kronos Bio stock.
We're not expecting Kronos Bio to pay a dividend over the next 12 months.
Kronos Bio's shares were split on a 3:2 basis on 2 November 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Kronos Bio shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Kronos Bio shares which in turn could have impacted Kronos Bio's share price.
Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.